Nasdaq

CSL Behring Demonstrates Continued Commitment to Alpha-1 Community with Addition of ZEMAIRA® [Alpha1-Proteinase Inhibitor (Human)] 4- and 5-Gram Vials

- 4- and 5-gram ZEMAIRA® vials may reduce the number of vials necessary for reconstitution, thereby providing convenience and lowering package waste KING OF PRUSSIA, Pa., Jan. 2, 2024 /PRNewswire/ -- ...
Monthly Prescribing Reference

Zemaira Now Available in 4- and 5-Gram Vials for Alpha

The dosing regimen for Zemaira is weight-based so the introduction of larger vial sizes reduces the number of reconstituted vials needed per dose. Zemaira (alpha 1-proteinase inhibitor [human]) is now ...
Nature

HIV-1 Protease Inhibitors and Resistance Mechanisms

HIV-1 protease inhibitors (PIs) have long been central to antiretroviral therapy, directly targeting the enzyme responsible for processing viral polyproteins into functional units. Their efficacy, ...
MarketWatch

Alpha-1 Antitrypsin Deficiency Market Research 2025-2035, Competitive Analysis of Grifols, CSL Behring, Takeda Pharmaceuticals, LFB Biotechnologies, GlaxoSmithKline ...

The "Alpha-1 Antitrypsin Deficiency Market - A Global and Regional Analysis: Focus on Treatment, Distribution Channel, and Regional Analysis - Analysis and Forecast, 2025-2035" report has been added ...
Nature

Sanofi buys Inhibrx and drug for alpha-1 antitrypsin deficiency for US$1.7 billion

Sanofi is buying Inhibrx for US$1.7 billion plus nearly $300 million in potential milestones. The deal is focused on INBRX-101, an enzyme replacement therapy that is currently in phase II trials for ...